Natera Inc. (NASDAQ: NTRA) appointed Thomas Lynch and Eric Rubin to its board of directors, the precision medicine company announced.

Lynch serves as President and Director of Fred Hutch Cancer Center and holds the Raisbeck Endowed Chair. He brings more than three decades of experience at cancer centers and previously held leadership positions including Chief Scientific Officer at Bristol-Myers Squibb, CEO of Massachusetts General Physicians Organization, and director of Yale Cancer Center.

Rubin has more than 35 years of experience in cancer drug development across academic and industry settings. He most recently served as senior vice president of global clinical oncology at Merck during a 16-year tenure, where he led the initial development of KEYTRUDA, the first anti-PD-1 therapy approved in the United States. He previously held faculty positions at Dana-Farber Cancer Institute and served as director of the investigational therapeutics division at Rutgers Cancer Institute of New Jersey.

Lynch joined the Human Capital Committee while Rubin joined the Nominating, Corporate Governance and Compliance Committee.

"Tom and Eric have helped lead some of the most important advances in modern oncology, and we are thrilled to welcome them to the Board," said Matthew Rabinowitz, co-founder and executive chairman of the board.

Lynch said molecular diagnostics will play a critical role as the oncology field moves toward more personalized treatment decisions. Rubin stated he looks forward to supporting the company as it continues advancing molecular diagnostics and expanding clinical evidence supporting precision oncology.

Natera focuses on cell-free DNA testing and precision medicine for oncology, women's health, and organ health applications.